Kazuma Oyama1,2, Robert P Giugliano1, David D Berg1, Christian T Ruff1, Petr Jarolim3, Minao Tang1, Sabina A Murphy1, Hans J Lanz4, Michael A Grosso5, Elliott M Antman1, Eugene Braunwald1, David A Morrow1. 1. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Suite 7022, Boston, MA 02115, USA. 2. Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. 3. Division of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. 4. Daiichi Sankyo, Zielstattstraße 48, München 81379, Germany. 5. Daiichi Sankyo, 211 Mt Airy Rd, Basking Ridge, NJ 07920, USA.
Abstract
AIMS: We investigated whether patients with atrial fibrillation (AF) demonstrate detectable changes in biomarkers including high-sensitivity troponin T (hsTnT), N-terminal B-type natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) over 12 months and whether such changes from baseline to 12 months are associated with the subsequent risk of stroke or systemic embolic events (S/SEE) and bleeding. METHODS AND RESULTS: ENGAGE AF-TIMI 48 was a randomized trial of the oral factor Xa inhibitor edoxaban in patients with AF and a CHADS2 score of ≥2. We performed a nested prospective biomarker study in 6308 patients, analysing hsTnT, NT-proBNP, and GDF-15 at baseline and 12 months. hsTnT was dynamic in 46.9% (≥2 ng/L change), NT-proBNP in 51.9% (≥200 pg/mL change), GDF-15 in 45.6% (≥300 pg/mL change) during 12 months. In a Cox regression model, upward changes in log2-transformed hsTnT and NT-proBNP were associated with increased risk of S/SEE [adjusted hazard ratio (adj-HR) 1.74; 95% confidence interval (CI) 1.36-2.23 and adj-HR 1.27; 95% CI 1.07-1.50, respectively] and log2-transformed GDF-15 with bleeding (adj-HR 1.40; 95% CI 1.02-1.92). Reassessment of ABC-stroke (age, prior stroke/transient ischaemic attack, hsTnT, and NT-proBNP) and ABC-bleeding (age, prior bleeding, haemoglobin, hsTnT, and GDF-15) risk scores at 12 months accurately reclassified a significant proportion of patients compared with their baseline risk [net reclassification improvement (NRI) 0.50; 95% CI 0.36-0.65; NRI 0.42; 95% CI 0.33-0.51, respectively]. CONCLUSION: Serial assessment of hsTnT, NT-proBNP, and GDF-15 revealed that a substantial proportion of patients with AF had dynamic values. Greater increases in these biomarkers measured over 1 year are associated with important clinical outcomes in anticoagulated patients with AF. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: We investigated whether patients with atrial fibrillation (AF) demonstrate detectable changes in biomarkers including high-sensitivity troponin T (hsTnT), N-terminal B-type natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) over 12 months and whether such changes from baseline to 12 months are associated with the subsequent risk of stroke or systemic embolic events (S/SEE) and bleeding. METHODS AND RESULTS: ENGAGE AF-TIMI 48 was a randomized trial of the oral factor Xa inhibitor edoxaban in patients with AF and a CHADS2 score of ≥2. We performed a nested prospective biomarker study in 6308 patients, analysing hsTnT, NT-proBNP, and GDF-15 at baseline and 12 months. hsTnT was dynamic in 46.9% (≥2 ng/L change), NT-proBNP in 51.9% (≥200 pg/mL change), GDF-15 in 45.6% (≥300 pg/mL change) during 12 months. In a Cox regression model, upward changes in log2-transformed hsTnT and NT-proBNP were associated with increased risk of S/SEE [adjusted hazard ratio (adj-HR) 1.74; 95% confidence interval (CI) 1.36-2.23 and adj-HR 1.27; 95% CI 1.07-1.50, respectively] and log2-transformed GDF-15 with bleeding (adj-HR 1.40; 95% CI 1.02-1.92). Reassessment of ABC-stroke (age, prior stroke/transient ischaemic attack, hsTnT, and NT-proBNP) and ABC-bleeding (age, prior bleeding, haemoglobin, hsTnT, and GDF-15) risk scores at 12 months accurately reclassified a significant proportion of patients compared with their baseline risk [net reclassification improvement (NRI) 0.50; 95% CI 0.36-0.65; NRI 0.42; 95% CI 0.33-0.51, respectively]. CONCLUSION: Serial assessment of hsTnT, NT-proBNP, and GDF-15 revealed that a substantial proportion of patients with AF had dynamic values. Greater increases in these biomarkers measured over 1 year are associated with important clinical outcomes in anticoagulated patients with AF. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Ziad Hijazi; Jonas Oldgren; Johan Lindbäck; John H Alexander; Stuart J Connolly; John W Eikelboom; Michael D Ezekowitz; Claes Held; Elaine M Hylek; Renato D Lopes; Agneta Siegbahn; Salim Yusuf; Christopher B Granger; Lars Wallentin Journal: Lancet Date: 2016-04-04 Impact factor: 79.321
Authors: Anny Camelo-Castillo; José Miguel Rivera-Caravaca; Francisco Marín; Vicente Vicente; Gregory Y H Lip; Vanessa Roldán Journal: Thromb Haemost Date: 2020-06-07 Impact factor: 5.249
Authors: Ziad Hijazi; Jonas Oldgren; Ulrika Andersson; Stuart J Connolly; Michael D Ezekowitz; Stefan H Hohnloser; Paul A Reilly; Agneta Siegbahn; Salim Yusuf; Lars Wallentin Journal: Heart Date: 2014-05-02 Impact factor: 5.994
Authors: Lars Wallentin; Ziad Hijazi; Ulrika Andersson; John H Alexander; Raffaele De Caterina; Michael Hanna; John D Horowitz; Elaine M Hylek; Renato D Lopes; Signild Asberg; Christopher B Granger; Agneta Siegbahn Journal: Circulation Date: 2014-10-07 Impact factor: 29.690
Authors: Norimitsu Ban; Carla J Siegfried; Jonathan B Lin; Ying-Bo Shui; Julia Sein; Wolfgang Pita-Thomas; Abdoulaye Sene; Andrea Santeford; Mae Gordon; Rachel Lamb; Zhenyu Dong; Shannon C Kelly; Valeria Cavalli; Jun Yoshino; Rajendra S Apte Journal: JCI Insight Date: 2017-05-04
Authors: Inder S Anand; Tibor Kempf; Thomas S Rector; Heike Tapken; Tim Allhoff; Franziska Jantzen; Michael Kuskowski; Jay N Cohn; Helmut Drexler; Kai C Wollert Journal: Circulation Date: 2010-09-20 Impact factor: 29.690
Authors: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Sabina A Murphy; Karen Brown; Petr Jarolim; Michele Mercuri; Elliott M Antman; David A Morrow Journal: JAMA Cardiol Date: 2016-12-01 Impact factor: 14.676
Authors: Felix Hofer; Ulrike Pailer; Patrick Sulzgruber; Christian Gerges; Max-Paul Winter; Robert P Giugliano; Michael Gottsauner-Wolf; Martin Hülsmann; Niema Kazem; Lorenz Koller; Robert Schönbauer; Alexander Niessner; Christian Hengstenberg; Thomas A Zelniker Journal: ESC Heart Fail Date: 2022-05-20